Advances in the optimization of therapeutic drug monitoring using serum, tissue and faecal anti-tumour necrosis factor concentration in patients with inflammatory bowel disease treated with TNF-α antagonists

Hasonló tételek

• Plasminogen activator inhibitor 1 is a novel faecal biomarker for monitoring disease activity and therapeutic response in inflammatory bowel diseases
  Szerző: Jójárt Boldizsár, et al.
  Megjelent: (2024)
• Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease
  Szerző: Pallagi-Kunstár Éva, et al.
  Megjelent: (2014)
• Tumour necrosis factor alpha gene (TNF-alpha)-376 polymorphism in Hungarian patients with primary progressive multiple sclerosis
  Szerző: Losonczi Erika, et al.
  Megjelent: (2009)
• Reverse Signaling Contributes to Control of Chronic Inflammation by Anti-TNF Therapeutics
  Szerző: Sipos Orsolya, et al.
  Megjelent: (2015)
• New Promising Combo Therapy in Inflammatory Bowel Diseases Refractory to Anti-TNF Agents Cyclosporine Plus Vedolizumab /
  Szerző: Szántó Kata Judit, et al.
  Megjelent: (2018)